Skip to main content

Analysts Are Neutral on Top Healthcare Stocks: Puma Biotechnology (PBYI), Cytek Biosciences (CTKB)

Tipranks - Tipranks - Fri Feb 27, 11:00PM CST

Analysts fell to the sidelines weighing in on Puma Biotechnology (PBYI – Research Report) and Cytek Biosciences (CTKB – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Claim 50% Off TipRanks Premium

Puma Biotechnology (PBYI)

In a report released yesterday, Marc Frahm from TD Cowen maintained a Hold rating on Puma Biotechnology, with a price target of $5.00. The company’s shares closed last Thursday at $7.60.

According to TipRanks.com, Frahm is a 5-star analyst with an average return of 19.5% and a 52.8% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Monte Rosa Therapeutics, Janux Therapeutics Inc, and Revolution Medicines. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Puma Biotechnology.

See today’s best-performing stocks on TipRanks >>

Cytek Biosciences (CTKB)

In a report released yesterday, Brendan Smith from TD Cowen maintained a Hold rating on Cytek Biosciences, with a price target of $5.00. The company’s shares closed last Thursday at $4.40, close to its 52-week low of $3.97.

According to TipRanks.com, Smith is a 3-star analyst with an average return of 2.9% and a 45.1% success rate. Smith covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Recursion Pharmaceuticals, and Ginkgo Bioworks Holdings. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cytek Biosciences with a $6.17 average price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).